There's Value in Studying Big Pharma Pipelines

Published: Jan 15, 2013

When analysts review a big pharma’s future prospects, they rightly focus on those drugs that are in the last stage of clinical trials (phase 3). These are the compounds for which the most is known and whose clinical programs are spelled out in detail on While not every compound in Phase 3 will successfully navigate the development process to FDA approval, a majority of them will, thus allowing analysts a sense of what is on the horizon.

Back to news